"Back-to-bedside", we observed a strong trend (even if not statistically significant, due to the size of our cohort) toward an increased radiologically-assessed response to MAPK inhibition therapy in BRAFV600- metastatic tumors containing a lower proportion of HuR Low cells (lower Z-score < −2SD) [35] .
← all excerpts
The human antigen R as an actionable super-hub within the network of cancer cell persistency and plasticity.
1
—
—